| 5 Oct 2026, 08:56 | First Patient Reaches Four Years in DMX-200 Clinical Program | Company Update | MS | 11001 |
| 28 Sept 2026, 14:34 | Notification regarding unquoted securities - DXB | Securities Administration | — | 06021 |
| 25 Sept 2026, 14:42 | Notification of 2026 Annual General Meeting Date | Meetings & Governance | — | 08006 |
| 23 Sept 2026, 08:44 | Dimerix Presents at ASX SMIDcaps Conference 2026 | Presentations | — | 03026 |
| 23 Sept 2026, 08:36 | Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility | Capital Raising | MS | 03022, 11001 |
| 22 Sept 2026, 15:46 | Waiver of Listing Rule 10.1 Granted | Capital Raising | — | 03022, 12016 |
| 16 Sept 2026, 08:31 | Dimerix Presents at E&P Healthcare Conference 2026 | Presentations | — | 03026 |
| 14 Sept 2026, 08:39 | Dimerix DMX-652 Granted Mexican Composition of Matter Patent | Company Update | MS | 11001 |
| 7 Sept 2026, 08:51 | Dimerix Investor Presentation | Presentations | — | 03026 |
| 4 Sept 2026, 17:10 | S&P DJI Announces September 2026 Quarterly Rebalance | Other | MS | — |
| 4 Sept 2026, 09:17 | Dimerix Secures A$34 Million Non-Dilutive Funding Facility | Capital Raising | MS | 03022, 09014 |
| 2 Sept 2026, 08:43 | Trading Halt | Trading Halt / Suspension | MS | 09007 |
| 27 Aug 2026, 08:56 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 |
| 27 Aug 2026, 08:56 | Appendix 4E and 2026 Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 |
| 20 Aug 2026, 09:13 | Dimerix Receives US$10M Upfront Payment from Everest | Company Update | MS | 11001 |
| 17 Aug 2026, 08:38 | Dimerix Assumes Sponsorship of US IND for New Asset DMX-652 | Company Update | MS | 11001 |
| 6 Aug 2026, 08:17 | Dimerix Presents at Bioshares Summit 2026 | Presentations | MS | 03026 |
| 30 July 2026, 08:49 | Dimerix Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19004, 19009 |
| 27 July 2026, 08:36 | Dimerix to Present at TechKnow Invest Conference 2026 | Presentations | — | 03026 |
| 23 July 2026, 08:46 | US Patent Granted for Dimerix New Asset DMX-652 | Company Update | MS | 11001 |
| 17 July 2026, 09:03 | Dimerix Investor Webinar | Presentations | — | 03026, 14014 |
| 17 July 2026, 09:03 | Dimerix Expands Pipeline with Acquisition of Phase 2 Asset | Company Update | MS | 11001 |
| 17 July 2026, 09:01 | Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway | Capital Raising | MS | 03022, 09014 |
| 15 July 2026, 08:42 | Trading Halt | Trading Halt / Suspension | MS | 09007 |
| 9 July 2026, 08:46 | DMX-200 Available To Patients Via Post-Trial Access Pathways | Company Update | MS | 11001 |
| 16 June 2026, 10:31 | Dimerix Investor Webinar | Presentations | — | 03026, 14014 |
| 16 June 2026, 10:20 | Dimerix Licenses DMX200 to Everest for China and Asia Region | Company Update | MS | 09014, 11001 |
| 15 June 2026, 09:13 | Trading Halt | Trading Halt / Suspension | MS | 09007 |
| 30 Apr 2026, 09:13 | Dimerix Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19003, 19008 |
| 28 Apr 2026, 10:26 | Dimerix Releases Investor Presentation and Video Recording | Company Update | — | 03026, 11001, 14014 |
| 28 Apr 2026, 09:20 | ACTION3 Statistical Review Complete | Company Update | MS | 11001 |
| 9 Apr 2026, 14:01 | Dimerix Singapore Investor Briefing | Company Administration | — | 12008 |
| 16 Mar 2026, 09:20 | Dimerix Presents at Euroz Hartleys Institutional Conference | Presentations | — | 03026 |
| 16 Mar 2026, 08:29 | Dimerix to Conduct Review of ACTION3 Statistical Assumptions | Company Update | MS | 11001 |
| 10 Mar 2026, 09:21 | Dimerix Phase 3 Trial Last Patient Receives First Dose | Company Update | MS | 11001 |
| 4 Mar 2026, 09:38 | Dimerix Invitation to Perth and Singapore Investor Briefings | Company Administration | — | 12008 |
| 27 Feb 2026, 09:23 | Dimerix Presents at Oppenheimer Life Sciences Conference | Presentations | — | 03026 |
| 26 Feb 2026, 09:30 | Appendix 4D and Half Year Financial Report | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 |
| 5 Feb 2026, 09:26 | Dimerix to Present at Euroz Hartleys Healthcare Forum 2026 | Presentations | — | 03026 |
| 29 Jan 2026, 09:39 | Quarterly Appendix 4C and Activities Report | Quarterly Reports | MS | 19002, 19007 |
| 21 Jan 2026, 08:28 | Appointment of CFO/Company Secretary | Company Administration | — | 12007, 12008 |
| 12 Jan 2026, 08:28 | Clinical trial update at J.P. Morgan Healthcare Conference | Presentations | — | 03026 |
| 24 Dec 2025, 08:36 | Dimerix receives input from FDA on ACTION3 trial endpoints | Company Update | — | 11001 |
| 22 Dec 2025, 09:16 | BioMarin to acquire Dimerix US Partner, Amicus Therapeutics | Company Update | MS | 11001 |
| 15 Dec 2025, 08:45 | DMX-200 ACTION3 Phase 3 Trial Completes Recruitment | Company Update | MS | 11001 |
| 12 Dec 2025, 14:50 | Change of Director's Interest Notice - CS,HA,NW,SP & MD | Director Interests | — | 02009 |
| 12 Dec 2025, 14:04 | Notification regarding unquoted securities - DXB | Securities Administration | — | 06021 |
| 19 Nov 2025, 09:05 | Successful Completion of Planned IDMC Review | Company Update | MS | 11001 |
| 18 Nov 2025, 16:58 | Results of AGM | Meetings & Governance | — | 08003 |
| 18 Nov 2025, 12:58 | Chair Address and AGM Presentation | Presentations | — | 03026, 15002 |